Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Jul 29;3(3):3055-72.
doi: 10.3390/cancers3033055.

Immunotherapy for urothelial carcinoma: current status and perspectives

Hiroshi Kitamura  1 , Taiji Tsukamoto
Affiliations

Immunotherapy for urothelial carcinoma: current status and perspectives

Hiroshi Kitamura et al. Cancers (Basel). .

Abstract

Intravesical instillation of bacillus Calmette Guérin (BCG) for the treatment of urothelial carcinoma (UC) of the bladder is based on the BCG-induced immune response, which eradicates and prevents bladder cancer. The results of recent studies have suggested that not only major histocompatibility complex (MHC)-nonrestricted immune cells such as natural killer cells, macrophages, neutrophils, etc., but also MHC-restricted CD8+ T cells play an important role and are one of the main effectors in this therapy. Better understanding of the mechanism of BCG immunotherapy supports the idea that active immunotherapy through its augmented T cell response can have great potential for the treatment of advanced UC. In this review, progress in immunotherapy for UC is discussed based on data from basic, translational and clinical studies. We also review the escape mechanism of cancer cells from the immune system, and down-regulation of MHC class I molecules.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Suggested cascade of immune response induced by intravesical BCG instillation.
See this image and copyright information in PMC

References

    1. Morales A., Eidinger D., Bruce A.W. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J. Urol. 1976;116:180–183. - PubMed
    1. Herr H.W., Morales A. History of bacillus Calmette-Guerin and bladder cancer: An immunotherapy success story. J. Urol. 2008;179:53–56. - PubMed
    1. Sternberg C.N., Yagoda A., Scher H.I., Watson R.C., Herr H.W., Morse M.J., Sogani P.C., Vaughan E.D., Jr., Bander N., Weiselberg L.R., et al. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. J. Urol. 1988;139:461–469. - PubMed
    1. Sternberg C.N., Yagoda A., Scher H.I., Watson R.C., Geller N., Herr H.W., Morse M.J., Sogani P.C., Vaughan E.D., Bander N., et al. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Cancer. 1989;64:2448–2458. - PubMed
    1. von der Maase H., Hansen S.W., Roberts J.T., Dogliotti L., Oliver T., Moore M.J., Bodrogi I., Albers P., Knuth A., Lippert C.M., et al. Visseren-Grul C.M., Conte P.F. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. Amer. J. Clin. Oncol. 2000;18:3068–3077. - PubMed